ALFA Finder| Revenue growth | 15.8% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin improved from 24.1% to 24.5% YoY. |
| Demand visibility | Strong, driven by 5-pillar domestic strategy and new product launches. |
| Management confidence | High; citing market-beating growth and entering Top 50 Pharma list. |
Growth
Revenue reached Rs 195.7 Cr (+15.8% YoY). EBITDA grew 17.9% to Rs 48 Cr with 24.5% margins.
Outlook
Targeting Naprosyn as a 100cr+ brand and growing immunosuppressants to 200cr+. Rs 185cr+ capex infused since FY22.
Risks
API growth previously impacted by a fire incident; ongoing dependency on regulatory approvals for international expansion.
Investor Presentation filed with NSE, NSE: RPGLIFE. Summary written with AI assistance from the document.
RPG Life Sciences Ltd: key numbers
- Share price
- ₹2,606.20
- Market cap
- ₹4,310 Cr
- Revenue (annual)
- ₹707.5 Cr
- Net profit (annual)
- ₹115.2 Cr
- P/E (TTM)
- 39.4×Sector 43.8×
- Promoter holding
- 72.95%+0.00% QoQ
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RPG Life Sciences Ltd
All →RPG Life Sciences Earnings Call Transcript: Key Takeaways
RPG Life Sciences delivered record quarterly revenue exceeding ₹200 Cr, driven by volume-led growth in domestic formulations and strategic API acquisitions. Management maintains a focus on premiumization and operational efficiency despite West Asia supply headwinds.
- Call
- Guides 25% growth
RPG Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹211.6 cr (+16.5%), adj PAT ₹32.3 cr (+13.4%), PAT margin 15.3%. API sales up 89%; domestic formulations +11.6%, international +6.4%.
RPG Life Sciences Results Update
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, growing 16.5%, and adjusted EBITDA of ₹50.1 crore. The API business integration continues to progress.
RPG Life Sciences Q2 FY27 Results: Net Profit ₹28.2 Cr, Down 23.6% YoY
RPG Life Sciences Ltd reported revenue from operations of ₹211.6 Cr (+16.5% YoY) and net profit of ₹28.2 Cr (-23.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹28.2 Cr · -23.6% YoY
RPG Life Sciences Board Meeting Date
RPG Life Sciences Limited has scheduled a board meeting on October 29, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
RPG Life Sciences Other Announcement
This is the quarterly shareholding pattern filing for RPG Life Sciences Ltd for the quarter ended September 30, 2026.